Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

Seeing is Believing: A Gene Therapy Success

Loading video...

 
   
Air date: Wednesday, December 15, 2010, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views:  
Category: Wednesday Afternoon Lectures
Runtime: 00:56:17
Description: Gene therapy has the potential to reverse disease or prevent further deterioration of vision in patients with incurable inherited retinal degeneration. The demonstration of safe and stable recovery of retinal/visual function in 12 children and adults with Leber congenital amaurosis (LCA) due to RPE65 mutations in a trial being carried out at The Children’s Hospital of Philadelphia (CHOP), and encouraging results from four other clinical trials for LCA-RPE65 provide great hope for people with other more common blinding diseases. This presentation will describe the animal studies that led to the clinical trials and the latest safety and efficacy results in the LCA-RPE65 clinical trial being held at CHOP. This Phase 1-2 study is now >3 years past initiation. In addition, it will describe some of the challenges presented by the nature of the targeted disease itself, hurdles that have been navigated in order to conduct the study, and issues of importance for eventual approval of gene augmentation as a therapy for LCA and other blinding diseases.

The NIH Director's Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Debug: Show Debug
NLM Title: Seeing is believing : a gene therapy success [electronic resource] / Jean Bennett.
Series: NIH director's Wednesday afternoon lecture
Author: Bennett, Jean.
National Institutes of Health (U.S.)
Publisher:
Other Title(s): NIH director's Wednesday afternoon lecture
Abstract: (CIT): Gene therapy has the potential to reverse disease or prevent further deterioration of vision in patients with incurable inherited retinal degeneration. The demonstration of safe and stable recovery of retinal/visual function in 12 children and adults with Leber congenital amaurosis (LCA) due to RPE65 mutations in a trial being carried out at The Children"s Hospital of Philadelphia (CHOP), and encouraging results from four other clinical trials for LCA-RPE65 provide great hope for people with other more common blinding diseases. This presentation will describe the animal studies that led to the clinical trials and the latest safety and efficacy results in the LCA-RPE65 clinical trial being held at CHOP. This Phase 1-2 study is now >3 years past initiation. In addition, it will describe some of the challenges presented by the nature of the targeted disease itself, hurdles that have been navigated in order to conduct the study, and issues of importance for eventual approval of gene augmentation as a therapy for LCA and other blinding diseases.
Subjects: Clinical Trials as Topic
Dogs
Genetic Therapy--methods
Leber Congenital Amaurosis--therapy
Publication Types: Lectures
Webcasts
Download: To download this event, select one of the available bitrates:
[256k]  [512k]    How to download a Videocast
NLM Classification: WW 166
NLM ID: 101552207
CIT Live ID: 9566
Permanent link: http://videocast.nih.gov/launch.asp?16388

 

Podcast information
Audio Podcasts   Video Podcasts
  Description Runtime     Description Runtime
Listen to the podcast Enhanced Audio Podcast 56:17   Watch the podcast Enhanced Video Podcast 56:17